Albumin administration in the acutely ill: what is new and where next?

Jean-Louis Vincent (1) , James A. Russell (2) , Matthias Jacob (3) , Greg Martin (4) , Bertrand Guidet (5, 6) , Jan Wernerman (7) , Ricard Ferrer Roca (8) , Stuart A. Mccluskey (9) , Luciano Gattinoni (10)

1 ULB - Université libre de Bruxelles
2 UBC - University of British Columbia
3 University-Hospital Munich-Großhadern
4 Emory University [Atlanta, GA]
5 CHU Saint-Antoine [AP-HP]
6 iPLESP - Institut Pierre Louis d'Epidémiologie et de Santé Publique
7 Karolinska University Hospital [Stockholm]
8 UB - Universitat de Barcelona
9 University of Toronto
10 IRCCS - Istituti di Ricovero e Cura a Carattere Scientifico

Albumin solutions have been used worldwide for the treatment of critically ill patients since they became commercially available in the 1940s. However, their use has become the subject of criticism and debate in more recent years. Importantly, all fluid solutions have potential benefits and drawbacks. Large multicenter randomized studies have provided valuable data regarding the safety of albumin solutions, and have begun to clarify which groups of patients are most likely to benefit from their use. However, many questions remain related to where exactly albumin fits within our fluid choices. Here, we briefly summarize some of the physiology and history of albumin use in intensive care before offering some evidence-based guidance for albumin use in critically ill patients .

Domaines: Médecine humaine et pathologie

Jean-Louis Vincent, James A. Russell, Matthias Jacob, Greg Martin, Bertrand Guidet, et al.. Albumin administration in the acutely ill: what is new and where next?. Critical Care, 2014, 18 (4), pp.231. ⟨10.1186/cc13991⟩. ⟨hal-01313544⟩